Compare Ecopetrol SA (EC) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs GSK plc — how do they compare? Ecopetrol SA trades at $17.1 (market cap $33.11B), while GSK plc trades at $46.82 (market cap $91.88B). The key difference: GSK plc is far larger — about 2.8× Ecopetrol SA's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and GSK plc for 93 Days on average.
| EC | GSK | |
|---|---|---|
Market Cap | $33.11B | $91.88B |
Volume | 993,598 | 7,730,529 |
Sector | Energy | Health |
52-Week High | $18.26 | $61.18 |
52-Week Low | $8.61 | $43.24 |
Typical Hold Time | 84 Days | 93 Days |
Enterprise Value | $61.36B | $111.88B |
Dividend Yield | 3.83% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.63, down 1.95% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 7.97 and P/S of 0.91, but faces declining revenue trends from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while analyst sentiment remains cautious with 27% buy ratings.
The outlook remains challenged by declining profitability and political interference risks, though current valuations appear discounted. Investment opportunity exists if new management can stabilize operations, but investors face headwinds from earnings volatility and geopolitical factors in Colombia's state-controlled energy sector.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
